Unsurprisingly, we did not observe any difference in tumor growth upon implantation of B16F10 cells into tamoxifen-treated Ptpn6fl/flERT2-Cre and Ptpn6fl/fl mice, suggesting that Shp1 loss alone is not sufficient to drive anti-tumor immunity in this “immune desert” tumor (Figure 4B). Here, PTPN6 is linked to neoplasm.